Topic:

R&D

Latest Headlines

Latest Headlines

RNAi specialist Alnylam to focus on three therapeutic areas

Saying it is on track to exceed its goal of having 5 key products in clinical development through 2015, Alnylam recently announced that it intends to focus on three strategic therapeutic areas, or what it dubs "STArs," as it races to commercialize its first candidate delivered using the RNAi pathway and reassure sometimes antsy investors.

Study: Universal dengue vaccine may be possible thanks to antibody discovery

So far, Sanofi's dengue candidate, the furthest along in the clinic, has struggled to ward off all four dengue viruses. But now, researchers have discovered new antibodies that could lead to a vaccine that does just that.

Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval

It's been a good news, bad news week for Novartis and its oncology business. Monday, the Swiss drugmaker won FDA approval for a long-acting version of Signifor, to treat acromegaly, a rare endocrine disorder. But Friday, Novartis announced that Afinitor fell short in a HER2-positive breast cancer trial, dashing hopes for what could have been a lucrative new indication.

Billionaire Soon-Shiong dives into immuno-oncology with $20M Sorrento venture

Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop therapies that harness the body's immune system to fight cancer.

DaVita grows its in-house CRO with a data-centric merger

Kidney dialysis magnate DaVita HealthCare Partners has merged its two research-minded subsidiaries to create an end-to-end CRO focused on renal trials.

Novartis psoriasis prospect tops J&J's fast-growing Stelara in PhIII

J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested the drug in a head-to-head trial.

Novartis' bid to widen Afinitor's breast cancer reach falls short in PhIII

Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod for HER2-positive advanced breast cancer. But no such luck: On Friday, the drugmaker announced its treatment had come up short in a Phase III trial.

Kansas State researchers model U.S. outbreak of foot-and-mouth

Veterinary researchers at Kansas State University have put together what they call the largest model of its kind that evaluates the effect and control of a potential outbreak of foot-and-mouth disease in livestock located in the central U.S.

Merck hits a hiccup with its new Ebola vaccine

Investigators have suspended a Phase I study of NewLink Genetics' Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant's plans to quickly ramp up production.

Naurex posts the positive PhIIb data that helped it reel in $80M

Fresh from raising $80 million and being featured in  The New York Times, Naurex has posted Phase IIb data to back up its belief it will be the company that finally turns the receptor affected by party drug Special K into a viable target for treatment of depression.